Cargando…

Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer

Tyrosine kinase inhibitors (TKI) play a pivotal role in the treatment of non-small-cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma kinase (ALK). However, the influences of TKIs on the tumor immune microenvironment (TIM), es...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Yisheng, Wang, Yuanyuan, Zeng, Dongqiang, Zhi, Shimeng, Shu, Tingting, Huang, Na, Zheng, Siting, Wu, Jianhua, Liu, Yantan, Huang, Genjie, Xue, Yichen, Bin, Jianping, Liao, Yulin, Shi, Min, Liao, Wangjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288040/ https://www.ncbi.nlm.nih.gov/pubmed/34345533 http://dx.doi.org/10.1080/2162402X.2021.1951019

Ejemplares similares

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Evolution of tumor microenvironment in colorectal liver metastases under treatment stress
por: Huang, Na, et al.
Publicado: (2022)

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases
por: Liao, Shan, et al.
Publicado: (2022)

A stroma‐related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early‐stage colon cancer
por: Zhou, Rui, et al.
Publicado: (2020)

A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I–III colon cancer
por: Zhou, Rui, et al.
Publicado: (2019)

Evaluation of stromal cell infiltration in the tumor microenvironment enable prediction of treatment sensitivity and prognosis in colon cancer
por: Zhou, Rui, et al.
Publicado: (2022)

Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β(2)‐AR/MACC1 axis
por: Pan, Changqie, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Immunosuppressive Microenvironment Revealed by Immune Cell Landscape in Pre-metastatic Liver of Colorectal Cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Expression pattern of secretory‐cell‐related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes
por: Zhou, Rui, et al.
Publicado: (2022)

Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response
por: Wu, Jiani, et al.
Publicado: (2021)

High baseline tumor burden‐associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2‐STAT3‐PD‐L1 pathway
por: Wen, Zhaowei, et al.
Publicado: (2023)

IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning
por: Ye, Zilan, et al.
Publicado: (2022)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
por: Wang, Hongbiao, et al.
Publicado: (2022)

Subsite‐specific metastatic organotropism and risk in gastric cancer: A population‐based cohort study of the US SEER database and a Chinese single‐institutional registry
por: Wang, Ling, et al.
Publicado: (2023)

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023)

PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients
por: Rong, Xiaoxiang, et al.
Publicado: (2022)

Corrigendum: PET/Ct Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients
por: Rong, Xiaoxiang, et al.
Publicado: (2022)

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
por: Huang, Quanfu, et al.
Publicado: (2019)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Gastric cancer cells escape metabolic stress via the DLC3/MACC1 axis
por: Lin, Li, et al.
Publicado: (2019)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer
por: Zhou, Rui, et al.
Publicado: (2018)

Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases
por: Zheng, Yannan, et al.
Publicado: (2023)

DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status
por: Yan, Rui, et al.
Publicado: (2023)

Olmesartan attenuates pressure-overload- or post-infarction-induced cardiac remodeling in mice
por: Wang, Qiancheng, et al.
Publicado: (2017)

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
por: Li, Mengmeng, et al.
Publicado: (2023)

ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance
por: Lin, Li, et al.
Publicado: (2019)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy
por: Sun, Huiying, et al.
Publicado: (2021)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
por: Zeng, Dongqiang, et al.
Publicado: (2020)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

HMGB1-RAGE Axis Makes No Contribution to Cardiac Remodeling Induced by Pressure-Overload
por: Lin, Hairuo, et al.
Publicado: (2016)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rcbhq9m8ijf77gha5144p5sta4